항뉴로필라멘트 L 항체 시장 예측(-2030년) : 제품 유형, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Anti Neurofilament L Antibody Market is accounted for $318.80 million in 2024 and is expected to reach $612.58 million by 2030 growing at a CAGR of 11.5% during the forecast period. Anti-neurofilament L (NfL) antibodies are specialized proteins made to attach to the neurofilament light chain (NfL), a structural protein that is widely present in neurons. Research and diagnosis of neurodegenerative illnesses like Alzheimer's, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are increasingly using NfL, a critical biomarker for identifying neuronal damage. These antibodies support early detection and monitoring of neurological diseases and are essential for the development of diagnostic assays, research into neuronal integrity, and advancement of therapeutic techniques.

According to Parkinson's Foundation, as of 2022, nearly one million people in the United States are living with Parkinson's disease (PD).

Market Dynamics:

Driver:

Rising prevalence of neurodegenerative diseases

The need for anti-neurofilament L (NfL) antibodies is mostly driven by the increasing incidence of neurodegenerative illnesses such as multiple sclerosis, Parkinson's, and Alzheimer's. NfL is an essential biomarker for identifying neuronal injury, which helps with early diagnosis and status monitoring. Advanced diagnosis technologies are becoming more and more necessary as populations age and the prevalence of these ailments rises worldwide. Furthermore, increased knowledge of the significance of NfL biomarkers among academics and healthcare professionals has accelerated their use in clinical and research settings, supporting the market's expansion.

Restraint:

Lack of standardized assay methods

The lack of standardized assay methods in the Anti-Neurofilament L (NfL) Antibody Market poses significant challenges, negatively impacting its growth. Assay protocol variability produces variable results, which compromises clinical diagnostics and research study reliability and reproducibility. This hinders wider adoption by undermining trust among academics, physicians, and regulatory agencies. Furthermore, the lack of common standards makes it more difficult to compare data from different studies, which slows down the development of new treatments and research on neurodegenerative diseases. In order to resolve this issue, stakeholders must work together to create norms that guarantee accuracy, uniformity, and wider accessibility.

Opportunity:

Advancements in biomarker research

Research on biomarkers is propelling the market for anti-neurofilament L (NfL) antibodies to rise significantly. Novel technologies such as ultrasensitive immunoassays (e.g., Simoa) have improved detection capabilities at previously unachievable levels since NfL was identified as a crucial biomarker for neurodegenerative disorders. These developments facilitate early diagnosis, tracking the course of the disease, and assessing the effectiveness of treatment, especially for diseases like multiple sclerosis, Alzheimer's, and ALS. Pharmaceutical corporations are now investing in biomarker studies as a result of research advances that have demonstrated the usefulness of NfL in clinical trials.

Threat:

Potential for false positive and negative results

While NfL is a promising biomarker for neurodegenerative diseases, there is a risk of false positive and negative results, which can significantly impact clinical decision-making. Factors such as sample handling, storage conditions, and the presence of interfering substances can influence the accuracy of NfL measurements. Additionally, variations in individual NfL levels can make it challenging to establish definitive diagnostic thresholds. To minimize the risk of false results, it is essential to optimize assay protocols, use high-quality reagents, and implement rigorous quality control measures.

Covid-19 Impact

Anti-Neurofilament L (NfL) antibody sales have been greatly influenced by the COVID-19 epidemic. Since COVID-19 has been linked to neurological symptoms like neuroinflammation and neurodegeneration, there has been more interest in NfL as a possible biomarker for determining the extent of neurological damage and tracking the course of the illness. As a result, there is now more demand for NfL antibodies for both diagnostic and research applications. The adoption of NfL-based diagnostic tests may also be influenced by the pandemic's acceleration of the development of remote healthcare solutions.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to be the largest, due to their high specificity, sensitivity, and reproducibility make them ideal for detecting and quantifying NfL levels in various biological samples. Monoclonal antibodies can be engineered to target specific epitopes on the NfL protein, enabling precise and accurate measurements. Additionally, advances in monoclonal antibody technology have led to the development of highly sensitive and specific assays, further driving the growth of the market.

The academic institutions segment is expected to have the highest CAGR during the forecast period

The academic institutions segment is anticipated to witness the highest CAGR during the forecast period. These institutions conduct extensive research on neurodegenerative diseases, utilizing NfL as a valuable biomarker to understand disease mechanisms and identify potential therapeutic targets. The demand for high-quality NfL antibodies for research purposes fuels the market's growth. Additionally, academic collaborations with pharmaceutical companies and biotechnology firms accelerate the development of innovative NfL-based diagnostic tools and therapeutic interventions.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rapidly aging population, rising neurological disease rates, and expanding medical facilities. The need for sophisticated diagnostic instruments like NfL tests has increased significantly because to the region's high population and growing healthcare expenditures. The market's expansion is also being driven by an increase in government programs to support healthcare and medical research. The demand for NfL antibodies is anticipated to increase as the region develops further, making it a crucial market for international companies.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, because of a developed healthcare infrastructure, a growing senior population, and a strong emphasis on healthcare research and development. The increasing incidence of neurodegenerative illnesses like ALS and Alzheimer's in the area has raised the need for precise and sensitive biomarkers like NfL. Furthermore, the development and marketing of NfL-based diagnostic tests and therapeutic interventions have been expedited by the presence of prominent pharmaceutical and biotechnology firms in North America.

Key players in the market

Some of the key players profiled in the Anti Neurofilament L Antibody Market include Merck KGaA, Abcam plc, Thermo Fisher Scientific Inc., Santa Cruz Biotechnology, Inc., Proteintech Group, Inc., R&D Systems, Inc., Boster Biological Technology, Rockland Immunochemicals Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., GeneTex, Inc., Novus Biologicals, LLC, ProSci Inc., Atlas Antibodies AB, LifeSpan BioSciences, Inc., Creative Biolabs, BioLegend, Inc., Abnova Corporation, PeproTech, Inc., and US Biological Life Sciences.

Key Developments:

In October 2023, Quanterix Corporation launched a new high-sensitivity assay for measuring neurofilament light chain (NfL) levels, aimed at enhancing the early detection and monitoring of neurodegenerative diseases.

In September 2023, BioLegend introduced a new anti-neurofilament L antibody aimed at research applications, providing enhanced specificity and sensitivity for studying neurodegeneration.

In April 2023, Merck KGaA released an updated version of their anti-neurofilament L antibody, which includes improved formulations for better performance in clinical diagnostics.

Product Types Covered:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Product Types

Applications Covered:

• Research
• Diagnostics
• Drug Discovery and Development
• Therapeutics
• Other Applications

End Users Covered:

• Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Anti Neurofilament L Antibody Market, By Product Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies
• 5.3 Polyclonal Antibodies
• 5.4 Other Product Types

6 Global Anti Neurofilament L Antibody Market, By Application

• 6.1 Introduction
• 6.2 Research
• 6.3 Diagnostics
• 6.4 Drug Discovery and Development
• 6.5 Therapeutics
• 6.6 Other Applications

7 Global Anti Neurofilament L Antibody Market, By End User

• 7.1 Introduction
• 7.2 Academic Institutions
• 7.3 Pharmaceutical and Biotechnology Companies
• 7.4 Laboratories
• 7.5 Other End Users

8 Global Anti Neurofilament L Antibody Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Merck KGaA
• 10.2 Abcam plc
• 10.3 Thermo Fisher Scientific Inc.
• 10.4 Santa Cruz Biotechnology, Inc.
• 10.5 Proteintech Group, Inc.
• 10.6 R&D Systems, Inc.
• 10.7 Boster Biological Technology
• 10.8 Rockland Immunochemicals Inc.
• 10.9 Bio-Rad Laboratories, Inc.
• 10.10 Cell Signaling Technology, Inc.
• 10.11 GeneTex, Inc.
• 10.12 Novus Biologicals, LLC
• 10.13 ProSci Inc.
• 10.14 Atlas Antibodies AB
• 10.15 LifeSpan BioSciences, Inc.
• 10.16 Creative Biolabs
• 10.17 BioLegend, Inc.
• 10.18 Abnova Corporation
• 10.19 PeproTech, Inc.
• 10.20 US Biological Life Sciences